SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Transcend Therapeutics (TSND) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3)3/11/1998 11:25:00 PM
From: John Metcalf  Read Replies (2) | Respond to of 25
 
I know better than to chase a one-product biotech, BUT --

the ARDS Ph III trial will be done this year
they have $16.8mm -- enough for six quarters at current burn
Nestle, Baxter, and Boehringer Ingleheim own shares
BI will market and sell Procysteine, if they get approval

A successful Ph III will make the company worth far more than $40mm.

Thanks, Rick



To: scaram(o)uche who wrote (3)3/12/1998 1:20:00 AM
From: scaram(o)uche  Read Replies (1) | Respond to of 25
 
Insiders own about 87% (eom)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News